ACCORD LIPID study results strengthen guideline approach of adding fenofibrate to therapy of dyslipidaemic type 2 diabetic patients.

Type 2 diabetic patients treated with statins but still experiencing elevated serum levels of triglycerides (2.3 mmol/l or higher) and low HDL cholesterol (0.8 mmol/l or lower), a pre-specified subgroup, benefited from the addition of fenofibrate to their treatment regimen. Risk of cardiovascular events was reduced by 31% in those patients, translating to a need-to-treat 20 patients for five years to prevent one cardiovascular event.